The Role of PD-L1 Expression As a Predictive Biomarker in Advanced Non-small-cell Lung Cancer: a Network Meta-analysis

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2016 Mar 15

PMID 26973128

Citations 80

Authors

Pedro N Aguiar Jr

Ilka Lopes Santoro

Hakaru Tadokoro

Gilberto de Lima Lopes

Bruno Andraus Filardi

Pedro Oliveira

Giannis Mountzios

Ramon Andrade de Mello

Affiliations

Soon will be listed here.

Abstract

Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer.

Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines.

Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06).

Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.

Citing Articles

Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach.

Lopez de Rodas M, Villalba-Esparza M, Sanmamed M, Chen L, Rimm D, Schalper K Nat Rev Clin Oncol. 2025; 22(3):163-181.

PMID: 39820025 DOI: 10.1038/s41571-024-00984-x.

Nanomedicines Targeting Tumor Cells or Tumor-Associated Macrophages for Combinatorial Cancer Photodynamic Therapy and Immunotherapy: Strategies and Influencing Factors.

Wei Y, Li R, Wang Y, Fu J, Liu J, Ma X Int J Nanomedicine. 2024; 19:10129-10144.

PMID: 39381025 PMC: 11460276. DOI: 10.2147/IJN.S466315.

Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab.

Svaton M, Knetki-Wroblewska M, Tabor S, Domecky P, Venclicek O, Krejci J In Vivo. 2024; 38(5):2434-2440.

PMID: 39187353 PMC: 11363798. DOI: 10.21873/invivo.13712.

Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.

Lim S, Kang S, Kim D, Lee S, Synn C, Baek S Cancer Res Commun. 2024; 4(7):1748-1764.

PMID: 38916448 PMC: 11253790. DOI: 10.1158/2767-9764.CRC-24-0107.

Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center.

Gikandi A, Chi S, Yeo K, ONeill A, Shulman D, Dubois S Cancer Med. 2024; 13(8):e7154.

PMID: 38629258 PMC: 11022150. DOI: 10.1002/cam4.7154.